By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mesoblast Limited 

Level 1, 843A Glenhuntly Road

Caulfield South  VIC  3162  Australia
Phone: 03-9618-7000 Fax:



Company News
Phase II Trial Results Show Mesoblast (MSB.AX) Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure 9/30/2015 7:11:47 AM
Full Product Approval In Japan Received By Mesoblast (MSB.AX) Licensee 9/18/2015 6:55:36 AM
Mesoblast (MSB.AX) Partner JCR Pharmaceuticals Receives Recommendation For Approval Of Mesenchymal Stem Cell Product In Japan 9/4/2015 7:06:59 AM
Mesoblast (MSB.AX) Reports 2015 Financial Year Results And Provides Update On Phase III Chronic Heart Failure Program 8/17/2015 5:56:55 AM
Mesoblast (MSB.AX) Release: Type 2 Diabetes Trial Results Published In Diabetes Care 7/23/2015 8:32:39 AM
Mesoblast (MSB.AX) Release: Congestive Heart Failure Phase Trial Results Published In Circulation Research 7/15/2015 6:58:30 AM
Postive Trial Results Of Mesoblast (MSB.AX) Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease 6/9/2015 7:27:30 AM
Mesoblast (MSB.AX) Release: Diabetic Nephropathy Trial Results Selected For Late-Breaking Presentation At American Diabetes Association Annual Meeting 5/18/2015 10:07:38 AM
Mesoblast (MSB.AX) Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study 5/12/2015 7:36:07 AM
Celgene (CELG), Mesoblast (MSB.AX) $45M Deal "Speaks Volumes" About Big Pharma's Cell Therapy Plans, Says Pluristem Therapeutics (PSTI) 4/14/2015 6:27:36 AM